News | December 05, 2021
Lupin and Biomm tie-up for pegfilgrastim in Brazil
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Subscribe To Our Newsletter & Stay Updated
